射血分数降低心衰对男女影响差异
该研究分析两项大型HFrEF试验中12,058名男性和3,357名女性,调整NT-proBNP等预后变量后,女性死亡率更低(aHR 0.68),但症状体征更多、生活质量更差,且利尿剂、抗凝药和器械治疗使用不足。
要点
- 女性HFrEF患者调整后死亡风险低于男性(aHR 0.68),心衰住院风险也较低(HR 0.80)。
- 女性症状体征更多、生活质量更差,KCCQ-CSS中位71.3 vs 81.3。
- 女性利尿剂、抗凝药及器械治疗使用不足,除颤器8.6% vs 16.6%。
核心结论
- 女性HFrEF患者生存期长于男性,但额外寿命质量较差,自报心理和躯体残疾更重。
- 女性仍接受次优治疗,原因不明,医生是否认识到这一差异亦未知。
研究设计与样本
- 分析两项大型HFrEF试验,纳入12,058名男性和3,357名女性,入选排除标准和主要结局几乎相同。
- 结局经其他预后变量调整,包括N末端B型利钠肽原。
主要发现
- 女性比男性年龄更大、更常肥胖,收缩压和心率略高,除高血压外多数合并症较少。
- 女性症状体征更多,如足部水肿23.4% vs 19.9%(p<0.0001)。
- 女性生活质量更差,KCCQ临床总结评分中位71.3(IQR 53.4-86.5)vs 81.3(IQR 65.1-92.7;p<0.0001),尽管LVEF和NT-proBNP相似。
- 女性死亡率更低(调整后HR 0.68;95%CI 0.62-0.74;p<0.001),心衰住院风险更低(HR 0.80;95%CI 0.72-0.89;p<0.001)。
- 利尿剂和抗凝药在女性中使用不足;器械治疗在男女中均使用不足,女性更甚(除颤器8.6% vs 16.6%;p<0.0001)。
临床怎么用
- 应关注女性HFrEF患者症状负担和生活质量,尽管其死亡风险较低。
- 需审视女性利尿剂、抗凝药及器械治疗使用不足的问题。
局限性
- 解释HFrEF性别相关体验差异的原因未知,医生是否认识到该差异亦未知。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Heart failure (HF) trials initiated in the last century highlighted many differences between men and women. Of particular concern was undertreatment of women compared with men, but much has changed during the past 20 years. OBJECTIVES: This study sought to identify these changes, which may give a new perspective on the management of, and outcomes in, women with HF. METHODS: The study analyzed 12,058 men and 3,357 women enrolled in 2 large HF with reduced ejection fraction (HFrEF) trials with near identical inclusion and exclusion criteria and the same principal outcomes. Outcomes were adjusted for other prognostic variables including N-terminal pro-B-type natriuretic peptide. RESULTS: Women were older and more often obese than men were, had slightly higher systolic blood pressure and heart rate, and were less likely to have most comorbidities, except hypertension. Women had more symptoms and signs (e.g., pedal edema 23.4% vs 19.9%; p < 0.0001) and worse quality of life-median Kansas City Cardiomyopathy Questionnaire Clinical Summary Score 71.3 (interquartile range: 53.4 to 86.5) versus 81.3 (interquartile range: 65.1 to 92.7; p < 0.0001)-despite similar left ventricular ejection fraction and N-terminal pro-B-type natriuretic peptide. However, women had lower mortality (adjusted hazard ratio: 0.68; 95% confidence interval: 0.62 to 0.74; p < 0.001) and risk of HF hospitalization (hazard ratio: 0.80; 95% confidence interval: 0.72 to 0.89; p < 0.001). Diuretics and anticoagulants were underutilized in women. Device therapy was underused in both men and women, but more so in women (e.g., defibrillator 8.6% vs. 16.6%; p < 0.0001). CONCLUSIONS: Although women with HFrEF live longer than men, their additional years of life are of poorer quality, with greater self-reported psychological and physical disability. The explanation for this different sex-related experience of HFrEF is unknown as is whether physicians recognize it. Women continue to receive suboptimal treatment, compared with men, with no obvious explanation for this shortfall.
引用
- Dewan P, Rørth R, Jhund PS, et al. Differential Impact of Heart Failure With Reduced Ejection Fraction on Men and Women. J Am Coll Cardiol. 2019. PMID: 30621948. doi:10.1016/j.jacc.2018.09.081
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。